Continuing the Success Story With TRK Inhibitors

Current preferences for testing patients with advanced solid tumors for NTRK gene fusions to help guide therapy based on treatment advances for TRK fusion-positive solid tumors.

David S. Hong, MD, of The University of Texas MD Anderson Cancer Center, discusses the availability of TRK inhibitors to treat advanced TRK fusion-positive solid tumors, highlighting their safety and efficacy.

The significance of recent data exploring larotrectinib, a TRK inhibitor, in a subset of patients with TRK fusion–positive tumors with CNS (central nervous system) metastasis.

Dr David S. Hong reacts to updated survival data associated with the use of larotrectinib as treatment for TRK fusion–positive non–small cell lung cancer.

Important takeaways from recent safety and efficacy data presented on the use of larotrectinib as treatment for advanced differentiated and anaplastic thyroid cancers with NTRK gene fusions.

David S. Hong, MD, of The University of Texas MD Anderson Cancer Center, shares his enthusiasm for ongoing research efforts to optimize treatment for patients with advanced solid tumors who harbor NTRK gene fusions.